No Data
GTJA: Continuous iteration of anti-tumor therapies, domestic new drugs welcome breakthroughs.
GTJA focuses on products with significant differentiation advantages and leading companies in innovative segments.
Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the
① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.
Jingfeng Pharmaceutical's Unit Gets Registration Certificate for Montelukast Sodium Chewable Tablets
*ST Jingfeng (000908.SZ): The subsidiary has received the Pharmaceutical registration certificate for Montelukast Sodium Chewable Tablets.
On February 10, 2023, *ST Jingfeng (000908.SZ) announced that recently, Hunan Jingfeng Pharmaceutical Co., Ltd.'s subsidiary Hainan Jinrui Pharmaceutical Co., Ltd. received the Drug Registration Certificate issued by the National Medical Products Administration for the Chemical Drug "Montelukast Sodium Chewable Tablets." Montelukast Sodium is a highly selective and potent leukotriene receptor antagonist that blocks the interaction between cysteinyl leukotrienes and receptors, thereby blocking the organ's response to leukotrienes, achieving the goal of controlling asthma. It is significantly effective in treating asthma and is suitable for the prevention and long-term treatment of asthma in children aged 2 to 14.
*ST Jingfeng: 2024 performance forecast
*Special Treat Jingfeng (000908.SZ): Expected profit for the year 2024 is between 0.11 billion yuan and -0.16 billion yuan.
*ST Jingfeng (000908.SZ) announced its performance forecast for 2024 on January 21. The total profit for 2024 is expected to be between 0.12 billion yuan and 0.16 billion yuan; the net income attributable to shareholders of the listed company is expected to be between 0.11 billion yuan and 0.16 billion yuan, turning from loss to profit year-on-year; the net income after deducting non-recurring gains and losses is expected to be a loss of between 68 million yuan and 100 million yuan; the basic EPS is expected to be between 0.13 yuan/share and 0.18 yuan/share; the revenue is expected to be between 0.38 billion yuan and 0.42 billion yuan, and the operating revenue after deductions is expected to be between 0.38 billion yuan and 0.42 billion yuan. During the reporting period, the company and
Even After Rising 19% This Past Week, Hunan Jingfeng PharmaceuticalLtd (SZSE:000908) Shareholders Are Still Down 49% Over the Past Five Years
